Greenland Mines Closes Sarfartoq Acquisition with $20M Cash and 1.4M Shares
GRML is trading near its 52-week low of $4.37 (10% above the low) on elevated volume (2.6× avg).
Summary
Greenland Mines completed its acquisition of the Sarfartoq rare earth project for US$20M cash plus 1.4M shares, securing a license with a $2.05B high-case NPV. Stockholders also approved contingent share issuances and the Series C conversion was restricted until 2027 or a $15 share price.
Key Events · M&A and Partnerships · GRML
-
Sarfartoq Acquisition Completed
The acquisition of NNSR Holdings Inc. has closed, indirectly transferring the Sarfartoq mineral license in Greenland. Total consideration: US$20M cash plus 1,040,676 common shares and 359,324 Series R preferred shares.
-
Project Economics Highlighted
The Sarfartoq Initial Assessment shows a pre-tax NPV of approximately $2.05B and IRR of 118.6% under the high case, based on the ST1 deposit occupying under 1% of the 191 sq km license.
-
Series R Preferred Stock Issued
359,324 Series R preferred shares were issued with no voting or conversion rights until stockholder approval; each share converts to one common share upon approval.
-
Series C Conversion Restricted
Series C preferred conversion is limited until the earlier of January 8, 2027 or five consecutive trading days with Nasdaq closing price at or above $15.00 per share.
Analysis · GRML · Life Sciences
The acquisition of the Sarfartoq rare earth project in Greenland is now complete, with Greenland Mines paying US$20 million in cash plus 1.4 million shares—1,040,676 common and 359,324 Series R preferred. This secures a mineral license underpinning a project with a pre-tax NPV of approximately $2.05 billion and 118.6% IRR under the high case. While the equity component is modest relative to the company's market cap, the transaction is transformative: it converts a development-stage company into a holder of a potentially world-class rare earth asset. The Series R preferred shares carry no voting or conversion rights until stockholder approval, limiting immediate dilution. Separately, the Series C preferred conversion restriction until January 2027 or a $15.00 share price removes a near-term overhang. Stockholders also approved issuance of up to 40.8 million shares upon Series C conversion and 691,039 shares upon warrant exercise, though these remain contingent on future conversions or exercises.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRML was trading at $4.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $4.37 to $36.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.